bluebird bio Inc. (BLUE)

168.90
NASDAQ : Health Technology
Prev Close 187.35
Day Low/High 166.43 / 187.95
52 Wk Low/High 85.65 / 236.17
Avg Volume 705.30K
Exchange NASDAQ
Shares Outstanding 50.12M
Market Cap 9.39B
EPS -7.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral...

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207)...

Bluebird Bio Announces Investor Events In June

Bluebird Bio Announces Investor Events In June

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference, Thursday, June 7, at 10:00 a.

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

bluebird bio, Inc. ( Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral presentations at the 23 rd Congress of the...

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE) announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology...

Chart of the Day: BLUE

The setup on bluebird bio is nice, with the stock overbought but not yet overheated.

Bluebird Bio To Present At Investor Conferences In May

Bluebird Bio To Present At Investor Conferences In May

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank's 43 rd Annual Health Care Conference, Wednesday, May 9, at 10:00 a.

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2018.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Celgene Shares Higher on Co-Development Pact With Bluebird

Celgene Shares Higher on Co-Development Pact With Bluebird

The biotech firms will work to develop and promote a potential treatment for relapsed and refractory multiple myeloma.

Bluebird Bio And Celgene Corporation Enter Into Agreement To Co-Develop And Co-Promote Anti-BCMA CAR T Cell Therapy Bb2121 In The United States

Bluebird Bio And Celgene Corporation Enter Into Agreement To Co-Develop And Co-Promote Anti-BCMA CAR T Cell Therapy Bb2121 In The United States

bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Bluebird Bio To Present At Investor Conferences In March

Bluebird Bio To Present At Investor Conferences In March

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced...

Bluebird Bio Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported...

Bluebird Bio Appoints Alison Finger As Chief Commercial Officer

Bluebird Bio Appoints Alison Finger As Chief Commercial Officer

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed...

Bluebird Bio To Present At LEERINK Partners Global Healthcare Conference

Bluebird Bio To Present At LEERINK Partners Global Healthcare Conference

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Bluebird Bio Announces Closing Of Over-Allotment Option In Public Offering

Bluebird Bio Announces Closing Of Over-Allotment Option In Public Offering

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Bluebird Bio To Present At Investor Conferences In January

Bluebird Bio To Present At Investor Conferences In January

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an...

TheStreet Quant Rating: D+ (Sell)